Cormorant Asset Management, LP Verve Therapeutics, Inc. Transaction History
Cormorant Asset Management, LP
- $1.27 Billion
- Q4 2024
A detailed history of Cormorant Asset Management, LP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 350,000 shares of VERV stock, worth $2.09 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
350,000
Previous 350,000
-0.0%
Holding current value
$2.09 Million
Previous $1.69 Million
16.53%
% of portfolio
0.16%
Previous 0.12%
Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
180Shares Held
76.4MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$73.7 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$41.2 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$39.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$23.9 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$23.9 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $358M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...